All In Biotech

Drug Trial Radar · NCT03577899

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

Last checked: Nov 20, 2026Latest source record: Jun 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 1,157 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,157

Actual

Start

Sep 25, 2018

Primary completion

Sep 25, 2020

Study completion May 19, 2021

Sponsor

Sponsor type
Industry
First posted
Jul 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • 0.5 mg Conbercept Intravitreal InjectionBiological

    Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.

  • 1.0 mg Conbercept Intravitreal InjectionBiological

    Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.

  • 2.0 mg Aflibercept Intravitreal InjectionBiological

    Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eyeTime frame: Baseline to Week 36

Locations

179 sites in 22 countries. Site status is shown where the registry gives one.

  • Kanghong Investigative Site

    Phoenix, Arizona

  • Kanghong Investigative Site

    Tucson, Arizona

  • Kanghong Investigative Site

    Beverly Hills, California

  • Kanghong Investigative Site

    Campbell, California

  • Kanghong Investigative Site

    Fullerton, California

  • Kanghong Investigative Site

    Glendale, California

  • Kanghong Investigative Site

    La Jolla, California

  • Kanghong Investigative Site

    Mountain View, California

  • Kanghong Investigative Site

    Oakland, California

  • Kanghong Investigative Site

    Palm Desert, California

  • Kanghong Investigative Site

    Palm Desert, California

  • Kanghong Investigative Site

    Sacramento, California

  • Kanghong Investigative Site

    Walnut Creek, California

  • Kanghong Investigative Site

    Golden, Colorado

  • Kanghong Investigative Site

    Fort Myers, Florida

  • Kanghong Investigative Site

    Fort Myers, Florida

  • Kanghong Investigative Site

    Jacksonville, Florida

  • Kanghong Investigative Site

    Lakeland, Florida

  • Kanghong Investigative Site

    Ocala, Florida

  • Kanghong Investigative Site

    Orlando, Florida

  • Kanghong Investigative Site

    Plantation, Florida

  • Kanghong Investigative Site

    Sarasota, Florida

  • Kanghong Investigative Site

    St. Petersburg, Florida

  • Kanghong Investigative Site

    Tampa, Florida

  • Kanghong Investigative Site

    ‘Aiea, Hawaii

  • Kanghong Investigative Site

    Bloomington, Illinois

  • Kanghong Investigative Site

    Chicago, Illinois

  • Kanghong Investigative Site

    Lemont, Illinois

  • Kanghong Investigative Site

    Wichita, Kansas

  • Kanghong Investigative Site

    Paducah, Kentucky

  • Kanghong Investigative Site in MD

    Hagerstown, Maryland

  • Kanghong Investigative Site

    Hagerstown, Maryland

  • Kanghong Investigative Site

    Boston, Massachusetts

  • Kanghong Investigative Site

    Detroit, Michigan

  • Kanghong Investigator Site

    Bloomfield, New Jersey

  • Kanghong Investigative Site

    Albany, New York

  • Kanghong Investigative Site

    Hauppauge, New York

  • Kanghong Investigative Site

    Rochester, New York

  • Kanghong Investigative Site

    Cincinnati, Ohio

  • Kanghong Investigative Site

    Cleveland, Ohio

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.